The Business Model

Our business model relates to drug development in neurodegenerative diseases and in Oncology where Ion Channel protein target(s) seem to be driving tumor progression and maintenance of a tumorigenic and metastatic potential.

Novassay develops novel leads across selected indications aiming to achieve at first step a strong pre-clinical Proof of Concept (Pre-Clin PoC) and then a clinical Proof of Concept (PoC, Phase II). Assets developed internally are open to partnering for subsequent clinical development.
Novassay has 100% exclusive ownership to all of its intellectual property portfolio which includes granted patents in major jurisdictions and also patent applications with the USPTO.